Search Results for: HSP90AA1

164 interactions involving HSP90AA1 - heat shock protein 90 alpha family class A member 1 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
KDR kinase insert domain receptor
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • ABT-869
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
KEAP1 kelch like ECH associated protein 1
  • Ub-specific processing proteases
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Dimethyl fumarate
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LINC01554 long intergenic non-protein coding RNA 1554
LSM1 LSM1 homolog, mRNA degradation associated
  • mRNA decay by 5' to 3' exoribonuclease
  • mRNA decay by 5' to 3' exoribonuclease
MAP3K14 mitogen-activated protein kinase kinase kinase 14
  • CD28 dependent PI3K/Akt signaling
  • Dectin-1 mediated noncanonical NF-kB signaling
  • TNFR2 non-canonical NF-kB pathway
  • NIK-->noncanonical NF-kB signaling
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
MAP3K3 mitogen-activated protein kinase kinase kinase 3
  • Interleukin-1 signaling
  • Fostamatinib
MAPK1 mitogen-activated protein kinase 1
  • phospho-PLA2 pathway
  • RAF-independent MAPK1/3 activation
  • MAPK1 (ERK2) activation
  • Spry regulation of FGF signaling
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • Recycling pathway of L1
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signal attenuation
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by MAPK mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Growth hormone receptor signaling
  • Acetylsalicylic acid
  • Minocycline
  • Isoprenaline
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • Seliciclib
  • Perifosine
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • Turpentine
  • Ulixertinib
MAPT microtubule associated protein tau
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Flortaucipir F-18
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
MIS12 MIS12 kinetochore complex component
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
MMP2 matrix metallopeptidase 2
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Extra-nuclear estrogen signaling
  • Marimastat
  • Captopril
  • SC-74020
  • Halofuginone
  • AE-941
  • Endostatin
  • Choriocarcinoma
  • Penile cancer
  • Torg-Winchester syndrome
MS4A2 membrane spanning 4-domains A2
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Omalizumab
  • Asthma
MTRNR2L1 MT-RNR2 like 1
MUC1 mucin 1, cell surface associated
  • Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
  • Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
  • Defective GALNT12 causes colorectal cancer 1 (CRCS1)
  • Dectin-2 family
  • Interleukin-4 and Interleukin-13 signaling
  • O-linked glycosylation of mucins
  • Termination of O-glycan biosynthesis
  • TG4010
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Acetylsalicylic acid
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer
MYOD1 myogenic differentiation 1
  • Myogenesis
  • Myogenesis
NDRG1 N-myc downstream regulated 1
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
NOS1 nitric oxide synthase 1
  • ROS and RNS production in phagocytes
  • Nitric oxide stimulates guanylate cyclase
  • Ion homeostasis
  • Citrulline
  • Donepezil
  • Ketamine
  • L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
  • Formic acid
  • 3-Bromo-7-Nitroindazole
  • N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine
  • N-[3-(aminomethyl)benzyl]acetamidine
  • L-N(omega)-nitroarginine-(4R)-amino-L-proline amide
  • 1-hydroxy-2-isopropylguanidine
  • N-omega-propyl-L-arginine
  • 2-butyl-1-hydroxyguanidine
  • S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
  • N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
  • Flavin adenine dinucleotide
  • Flavin mononucleotide
  • N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
  • Nicotinamide adenine dinucleotide phosphate
  • S-Ethyl-N-Phenyl-Isothiourea
  • [(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium
  • 5-N-Allyl-arginine
  • Nitroarginine
  • NXN-188
  • N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
  • N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
  • Methylene blue
NOS3 nitric oxide synthase 3
  • ROS and RNS production in phagocytes
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • NOSIP mediated eNOS trafficking
  • Nitric oxide stimulates guanylate cyclase
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • Arginine
  • Citrulline
  • Sapropterin
  • Miconazole
  • N,N-dimethylarginine
  • L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
  • Canavanine
  • 3-Bromo-7-Nitroindazole
  • N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine
  • N-[3-(aminomethyl)benzyl]acetamidine
  • 1,2,4-Triazole-Carboxamidine
  • L-N(omega)-nitroarginine-(4R)-amino-L-proline amide
  • S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
  • 7-Nitroindazole
  • S-Ethylisothiourea
  • 2-Aminothiazoline
  • Se-Ethyl-Isoselenourea
  • 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
  • N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
  • Cacodylic acid
  • 7-Nitroindazole-2-Carboxamidine
  • 6-Nitroindazole
  • N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
  • N(G)-Iminoethylornithine
  • 5,6-Cyclic-Tetrahydropteridine
  • S-Ethyl-N-Phenyl-Isothiourea
  • S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
  • 6S-5,6,7,8-Tetrahydrobiopterin
  • S-(Dimethylarsenic)Cysteine
  • L-homoarginine
  • S-Isopropyl-Isothiourea
  • Nitroarginine
  • 5-Nitroindazole
  • N-(Chlorophenyl)-N'-hydroxyguanidine
  • (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
  • 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
  • ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
  • N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
  • N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
  • Levamlodipine
NPAS2 neuronal PAS domain protein 2
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • PPARA activates gene expression
  • Circadian Clock

Page 5 out of 9 pages